Welcome to our dedicated page for Aurinia Pharmaceuticals news (Ticker: AUPH), a resource for investors and traders seeking the latest updates and insights on Aurinia Pharmaceuticals stock.
Aurinia Pharmaceuticals Inc (symbol: AUPH) is a cutting-edge biopharmaceutical company headquartered at 5120-75 street, Edmonton, Canada. Specializing in the treatment of serious diseases with high unmet medical need, Aurinia is committed to providing innovative therapeutic solutions to patients worldwide. The company's flagship product, LUPKYNIS (voclosporin), is an investigational drug designed for the treatment of lupus nephritis (LN), a severe renal complication of lupus. This groundbreaking treatment underscores Aurinia's focus on developing life-changing medications.
In recent years, Aurinia Pharmaceuticals has made significant strides in its research and development efforts, particularly in the United States, where it derives the majority of its revenue. The company has forged strategic partnerships with leading healthcare organizations and continues to explore new avenues for growth and innovation.
Financially, Aurinia has demonstrated strong performance, with consistent revenue growth driven by its robust pipeline of investigational drugs. The company's commitment to advancing its clinical programs and securing regulatory approvals positions it well for sustained success in the biopharmaceutical industry.
With a dedicated team of experts and a clear vision for the future, Aurinia Pharmaceuticals is poised to make a lasting impact on global healthcare. Investors and stakeholders can stay updated on the latest developments, financial results, and strategic initiatives through the company's regular news updates and investor relations communications.
Aurinia Pharmaceuticals (NASDAQ: AUPH) reported its financial results for Q4 and the year ended December 31, 2020, showing significant growth following the FDA approval and launch of LUPKYNIS for lupus nephritis. Revenues surged to $50.1 million, primarily due to a $50 million upfront payment from Otsuka. Despite a net loss of $102.7 million for the year, the company holds $423 million in cash and investments, sufficient to support operations into 2023. R&D expenses decreased to $50.3 million, while corporate expenses surged due to commercial infrastructure buildup.
Aurinia Pharmaceuticals (NASDAQ: AUPH) announced that its executive management will participate in a fireside chat at the SVB Leerink 10th Annual Global Healthcare Conference on February 25, 2021, at 1:00 p.m. ET. Interested parties can access the audio webcast through the “Investors” section on Aurinia's website, with a replay available afterward. Aurinia specializes in biopharmaceuticals, notably launching LUPKYNIS™, the first FDA-approved oral therapy for adult patients with active lupus nephritis.
Aurinia Pharmaceuticals (NASDAQ: AUPH) is set to release its fourth quarter and year-end 2020 financial results on February 24, 2021, post-market. A conference call will follow at 4:30 PM ET to discuss these results and provide a general business update. The call can be accessed via dial-in or through an audio webcast on Aurinia's website. The company is known for its FDA-approved treatment, LUPKYNIS™, targeting adult patients with active lupus nephritis.
Aurinia Pharmaceuticals has received FDA approval for LUPKYNIS (voclosporin), the first oral therapy for treating adult patients with active lupus nephritis (LN). This innovative treatment significantly improves renal response rates and accelerates decreases in urine protein levels compared to standard therapies. Clinical trials indicated that LUPKYNIS is more than twice as effective at achieving complete renal response. Aurinia has initiated the Aurinia Alliance program to support patients. This approval is a significant advancement for the lupus community, addressing a critical unmet need.
Aurinia Pharmaceuticals (NASDAQ: AUPH) announced that its management will participate in upcoming virtual investor conferences. Key events include an on-demand fireside chat at the H.C. Wainwright Virtual BioConnect 2021 Conference starting January 11, 2021, at 6:00 a.m. EST, and a panel discussion led by Dr. Scott Gottlieb at 12:00 p.m. EST on the same day. Additionally, a fireside chat at the J.P. Morgan 39th Annual Healthcare Conference is scheduled for January 14, 2021, at 4:30 p.m. EST. Interested parties can access the webcasts on Aurinia's corporate website.
Aurinia Pharmaceuticals (NASDAQ: AUPH) has announced a collaboration with Otsuka Pharmaceutical Co., Ltd. for the development of oral voclosporin, aimed at treating Lupus Nephritis (LN) in multiple regions including the EU and Japan. Aurinia will receive an upfront payment of $50 million, with potential milestone payments of up to $50 million and tiered royalties on net sales ranging from 10% to 20%. Otsuka plans to file for marketing authorization in the EU in Q2 2021. This agreement underscores Aurinia's goal to expand access to voclosporin globally for LN patients.
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) announced its participation in the Piper Sandler 32nd Annual Virtual Healthcare Conference. Presentations will be accessible to registered attendees until December 3. Interested parties can listen to the audio webcast by registering through the 'Investors' section of Aurinia's website. A replay will be available for 30 days. Aurinia focuses on developing therapies for serious diseases with high unmet medical needs, including seeking FDA approval for voclosporin for lupus nephritis treatment.
Aurinia Pharmaceuticals (NASDAQ:AUPH) announced the grant of a non-qualified stock option for 298,924 common shares to newly appointed Executive Vice President, Stephen Robertson. The options, with an exercise price of $13.40 per share, will vest in phases beginning November 2021. This grant complies with Nasdaq Listing Rule 5635(c)(4) and the TSX regulations. Aurinia is focused on developing therapies for high unmet medical needs, particularly voclosporin for lupus nephritis.
Aurinia Pharmaceuticals (NASDAQ: AUPH) announced that its senior management will participate in a fireside chat at the 2020 Jefferies Virtual London Healthcare Conference on November 19, 2020, at 11:25 a.m. ET. Interested parties can access the live audio webcast through the 'News/Events' section on Aurinia's corporate website. A replay will also be available. Aurinia Pharmaceuticals is focused on developing therapies for serious diseases with high unmet medical needs, currently seeking FDA approval for voclosporin to treat lupus nephritis.
Aurinia Pharmaceuticals reported its Q3 2020 financial results, showing a net loss of $34.1 million or $0.28 per share, compared to a loss of $19.0 million in Q3 2019. The company has $421 million in cash resources as of September 30, 2020, up from $306 million at the end of 2019. Its NDA for voclosporin received FDA Priority Review, with a PDUFA date set for January 22, 2021. R&D expenses fell to $4.8 million due to reduced clinical activities, while corporate expenses rose significantly to $31.1 million, reflecting preparations for the voclosporin launch.
FAQ
What is the current stock price of Aurinia Pharmaceuticals (AUPH)?
What is the market cap of Aurinia Pharmaceuticals (AUPH)?
What does Aurinia Pharmaceuticals Inc. specialize in?
Where is Aurinia Pharmaceuticals Inc. located?
What is LUPKYNIS (voclosporin)?
Where does Aurinia Pharmaceuticals derive most of its revenue?
What recent achievements has Aurinia Pharmaceuticals accomplished?
How can investors stay updated on Aurinia Pharmaceuticals' latest news?
What is the significance of LUPKYNIS for Aurinia Pharmaceuticals?
What type of diseases does Aurinia Pharmaceuticals focus on?
Has Aurinia Pharmaceuticals formed any partnerships?
What is the outlook for Aurinia Pharmaceuticals’ future?
